Data Insights

Navitoclax dihydrochloride by AbbVie for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval

Navitoclax dihydrochloride is under clinical development by AbbVie and currently in Phase III for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According...

Likelihood of Approval and Phase Transition Success Rate Model - Navitoclax Dihydrochloride in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)

Data Insights

Navitoclax dihydrochloride by AbbVie for Post-Polycythemia Vera Myelofibrosis (PPV-MF): Likelihood of Approval

Navitoclax dihydrochloride is under clinical development by AbbVie and currently in Phase III for Post-Polycythemia Vera Myelofibrosis (PPV-MF). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Navitoclax Dihydrochloride in Post-Polycythemia Vera Myelofibrosis (PPV-MF)

Data Insights

Navitoclax dihydrochloride by AbbVie for Myelofibrosis: Likelihood of Approval

Navitoclax dihydrochloride is under clinical development by AbbVie and currently in Phase III for Myelofibrosis. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - Navitoclax Dihydrochloride in Myelofibrosis

Data Insights

Navitoclax dihydrochloride by AbbVie for Non-Small Cell Lung Cancer: Likelihood of Approval

Navitoclax dihydrochloride is under clinical development by AbbVie and currently in Phase I for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Navitoclax Dihydrochloride in Non-Small Cell Lung Cancer

Data Insights

Navitoclax dihydrochloride by AbbVie for Myelodysplastic Syndrome: Likelihood of Approval

Navitoclax dihydrochloride is under clinical development by AbbVie and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Navitoclax Dihydrochloride in Myelodysplastic Syndrome

Data Insights

Navitoclax dihydrochloride by AbbVie for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

Navitoclax dihydrochloride is under clinical development by AbbVie and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Navitoclax Dihydrochloride in Relapsed Acute Myeloid Leukemia

Data Insights

Navitoclax dihydrochloride by AbbVie for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Navitoclax dihydrochloride is under clinical development by AbbVie and currently in Phase I for Refractory Acute Myeloid Leukemia. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Navitoclax Dihydrochloride in Refractory Acute Myeloid Leukemia

Data Insights

Navitoclax dihydrochloride by AbbVie for Essential Thrombocythemia: Likelihood of Approval

Navitoclax dihydrochloride is under clinical development by AbbVie and currently in Phase I for Essential Thrombocythemia. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Navitoclax Dihydrochloride in Essential Thrombocythemia

Data Insights

Navitoclax dihydrochloride by AbbVie for Polycythemia Vera: Likelihood of Approval

Navitoclax dihydrochloride is under clinical development by AbbVie and currently in Phase I for Polycythemia Vera. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Navitoclax Dihydrochloride in Polycythemia Vera

Data Insights

Navitoclax dihydrochloride by AbbVie for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis): Likelihood of Approval

Navitoclax dihydrochloride is under clinical development by AbbVie and currently in Phase III for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis). According...

Data Insights

Risk adjusted net present value: What is the current valuation of AbbVie's Navitoclax dihydrochloride?

Navitoclax dihydrochloride is a small molecule commercialized by AbbVie, with a leading Phase III program in Chronic Idiopathic Myelofibrosis (Primary...

Net Present Value Model: AbbVie Inc's Navitoclax dihydrochloride

Data Insights

Risk adjusted net present value: What is the current valuation of AbbVie's Navitoclax dihydrochloride?

Navitoclax dihydrochloride is a small molecule commercialized by AbbVie, with a leading Phase III program in Post-Essential Thrombocythemia Myelofibrosis (Post-ET...

Net Present Value Model: AbbVie Inc's Navitoclax dihydrochloride